Hanxiong Li is the Founder, Chairman and General Manager of ApicHope Pharmaceutical. Mr. Li hasreceived national honors including “China Outstanding Innovative Entrepreneur”, “China Outstanding Private Entrepreneur”, “China Outstanding Private Science and Technology Innovation Entrepreneur”, “Guangzhou Industry Leading Talent (Outstanding Industrial Talent)”, “Guangzhou Science and Technology Innovation Talent”, etc. He led the transformation of ApicHopePharmaceutical into an innovative bio-pharmaceutical company with integrated R&D, manufacturing and sales, which was listed on the Shenzhen Stock Exchange in November 2017 (300723.SZ).ApicHope is clinically need-oriented and has established a R&D center of 60,000square meters. ApicHope’s R&D area covers chronic disease drugs, anti-infective drugs, and pediatricdrugs, and has now expanded to vaccine therapy and precision medicine toward oncology. ApicHope has a strong marketing network and sales capability. Based on FDA & EU standards, ApicHope has built a biomedical intelligent industrial park in Guangzhou, covering an area of 220,000 square meters, integrated with information, digitalization and intelligence, which will be put into operation in 2022.